Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia

Condition(s) studied

Investigational drug(s) / intervention(s)

Pharmaceutical intervention: Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.

Study summary

The aim of this trial is therefore to identify concomitant treatments with taking Tyrosine Kinase Inhibitor (=TKI) in the indication of Chronic Myeloid Leukemia (CML), whatever the stage of the disease, via pharmaceutical conciliation. These concomitant treatments as well as their dosages will be correlated with the TKI dosage since patients must have a sufficient residual concentration to be considered effective and to confirm adherence to treatment, the leading cause of treatment failure.

In the event of unsatisfactory results, pharmaceutical interventions may take place: changes in treatments (TKI and not TKI) and / or dosages. In case of modification, a new dosage of TKI should be carried out.

Eligibility

Primary outcome measure(s)

• Number of patients for whom pharmaceutical interventions have been done — 12 months
  Number of patients for whom pharmaceutical interventions have been done secondly to pharmaceutical conciliation will be reported.

Trial sites (1)

More Centre Hospitalier Universitaire de Saint Etienne trials in France

Other trials for the same condition